Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lavender oil WS 1265 vs paroxetine vs placebo in generalized anxiety disorder
2006-000521-61Phase 3Completed
- Sponsor
- Schwabe Group
- Start
- Jun 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Silexan in generalized anxiety disorder (GAD) (3 arms), sponsored by Schwabe Group. Primary endpoint: Change in HAM-A total score from baseline to Week 10. Started Jun 2006; status: completed.
02
Drugs
Silexan
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2006-000521-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000521-61.